Pulmonary hypertension arising from left heart disease (PH-LHD) requires a management strategy that is distinct from other forms of pulmonary hypertension. The approach is centred on the cardiac condition underlying the elevated pulmonary pressures.
The primary strategy is optimizing treatment of the underlying cardiac disease. Where fluid retention is present, management is guided by a well-established class of agents that forms the cornerstone of medical therapy in this setting.
The complete regimen — including specific therapy selection, sequencing, and any relevant contraindications — is available in the full structured protocol.